Walker P - Search Results

1

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.

Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Ho PJ, et al. Among authors: walker p. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010. Epub 2019 May 16. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31208889

2

High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.

Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A. Low M, et al. Among authors: walker p. Intern Med J. 2013 Mar;43(3):294-7. doi: 10.1111/j.1445-5994.2012.02868.x. Intern Med J. 2013. PMID: 22757980 Review.

3

Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.

Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A, Wei A. Fong CY, et al. Among authors: walker p. Leuk Lymphoma. 2013 Feb;54(2):336-41. doi: 10.3109/10428194.2012.713479. Epub 2012 Sep 8. Leuk Lymphoma. 2013. PMID: 22812445

4

Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.

Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Govindaraj C, et al. Among authors: walker p. Clin Cancer Res. 2014 Feb 1;20(3):724-35. doi: 10.1158/1078-0432.CCR-13-1576. Epub 2013 Dec 2. Clin Cancer Res. 2014. PMID: 24297862 Clinical Trial.

5

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A. Tan P, et al. Among authors: walker p. Blood Cancer J. 2014 Jan 10;4(1):e170. doi: 10.1038/bcj.2013.68. Blood Cancer J. 2014. PMID: 24413064 Free PMC article.

6

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma.

Campbell P, Walker P, Avery S, Patil S, Curtis D, Schwarer A, Wei A, Kalff A, Muirhead J, Spencer A. Campbell P, et al. Among authors: walker p. Blood Cancer J. 2014 May 9;4(5):e213. doi: 10.1038/bcj.2014.33. Blood Cancer J. 2014. PMID: 24813081 Free PMC article. No abstract available.

7

Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia.

Doan TN, Kong DC, Patel K, Walker P, Spencer A, Kirkpatrick CM. Doan TN, et al. Among authors: walker p. Int J Antimicrob Agents. 2014 Nov;44(5):450-7. doi: 10.1016/j.ijantimicag.2014.07.019. Epub 2014 Sep 6. Int J Antimicrob Agents. 2014. PMID: 25261159

8

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.

Pham T, Patil S, Fleming S, Avery S, Walker P, Wei A, Curtis D, Stuart G, Klarica D, O'Brien M, Morris K, Das T, Bollard G, Muirhead J, Coutsouvelis J, Spencer A. Pham T, et al. Among authors: walker p. Transfusion. 2015 Nov;55(11):2709-13. doi: 10.1111/trf.13233. Epub 2015 Jul 14. Transfusion. 2015. PMID: 26173921

9

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

Doan TN, Kirkpatrick CM, Walker P, Slavin MA, Ananda-Rajah MR, Morrissey CO, Urbancic KF, Grigg A, Spencer A, Szer J, Seymour JF, Kong DC. Doan TN, et al. Among authors: walker p. J Antimicrob Chemother. 2016 Feb;71(2):497-505. doi: 10.1093/jac/dkv343. Epub 2015 Oct 30. J Antimicrob Chemother. 2016. PMID: 26518050

10

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.

Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, Ho J, Horvath N, King T, McNeil J, Mollee P, Quach H, Reid CM, Rosengarten B, Walker P, Spencer A. Bergin K, et al. Among authors: walker p. BMC Med Res Methodol. 2016 Nov 9;16(1):151. doi: 10.1186/s12874-016-0250-z. BMC Med Res Methodol. 2016. PMID: 27829380 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,086 results

Search Page